It is very uncertain whether diflunisal changes number of dropouts due to adverse events compared with placebo (very low certainty).
Patisiran may leads to lower number of dropouts due to adverse events compared with placebo (low certainty).
Inotersen may leads to higher number of dropouts due to adverse events compared with placebo (low certainty).
It is very uncertain whether tafamidis changes number of dropouts due to adverse events compared with placebo (very low certainty).
Lipid‐lowering agent showed no clear difference in adverse events (only reported for two studies: one study used CT… compared with placebo or no treatment (low certainty).
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).